Townsend Richard Nolan 4
4 · Lexeo Therapeutics, Inc. · Filed Nov 20, 2025
Insider Transaction Report
Form 4
Townsend Richard Nolan
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-11-18$9.27/sh−1,127$10,447→ 240,991 total
Footnotes (3)
- [F1]Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
- [F2]This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]Includes 128,357 Restricted Stock Units.